COMMUNIQUÉS West-GlobeNewswire

Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
02/07/2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 [...]
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2024
WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
02/07/2024
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities [...]
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
02/07/2024
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “ [...]
BrightSpring Health Services, Inc. to Announce Second Quarter 2024 Financial Results on August 2, 2024
02/07/2024
LOUISVILLE, Ky., July 02, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its second quarter 2024 financial results [...]
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
02/07/2024
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic [...]
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
02/07/2024
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/07/2024
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
02/07/2024
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important [...]
HNL Lab Medicine Enhances Emergency Care with Onboard Blood Transfusions
02/07/2024
ALLENTOWN, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- HNL Lab Medicine has partnered with Lehigh Valley Health Network (LVHN) to significantly improve emergency medical care. Effective immediately, the blood banks managed [...]
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
02/07/2024
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
02/07/2024
Aggregated presentation by day and by market Purchases of own shares from June 24th to 28th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2024
02/07/2024
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 24 au 28 juin 2024 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
02/07/2024
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 2 juillet 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Canadian Red Cross and Walmart Canada launch annual giving campaign
02/07/2024
Funds raised in support of building stronger and more resilient communities OTTAWA, July 02, 2024 (GLOBE NEWSWIRE) -- The Canadian Red Cross, in collaboration with Walmart Canada, is proud to announce the start of its [...]
La Croix-Rouge canadienne et Walmart Canada lancent leur campagne annuelle de dons
02/07/2024
Des fonds amassés pour créer des collectivités plus fortes et plus résilientes OTTAWA, 02 juill. 2024 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne, en collaboration avec Walmart Canada, est fière d’annoncer le [...]
Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialist
02/07/2024
On June 21, we finalized the acquisition of Globion's minority shares, bringing our stake to 100%. As planned, this transaction follows the acquisition of a 74% majority stake concluded on November 1, 2023. Founded in [...]
Virbac finalise l’acquisition des parts minoritaires de Globion, spécialiste indien des vaccins volaille
02/07/2024
Virbac finalise l’acquisition des parts minoritaires de Globion, spécialiste indien des vaccins volaille Le 21 juin, nous avons finalisé l'acquisition des parts minoritaires de Globion, portant ainsi notre participation [...]
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02/07/2024
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic [...]

Pages